Latest Headlines

1. Kymanox Acquires Agilis Consulting Group, A Trusted Human Factors Provider 3/24/2023

   Agilis is a trusted human factors partner for the global medical market. They specialize in helping new and established companies achieve successful HF submissions while navigating the complex global regulatory landscape, resulting in safe and effective medical products being brought to market.

2. Massive Bio And NeoGenomics Announce Collaboration To Accelerate Oncology Drug Discovery And Improve Patient Care 3/22/2023

   Massive Bio, Inc., a private AI-enabled oncology startup that provides virtual and in-person concierge services for cancer patients, and NeoGenomics, Inc. a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced a collaboration with the goal of accelerating the development of new cancer therapies and ultimately improving the lives of millions of cancer patients around the world.

3. Invitae And Deerfield Management Partner To Create Novel Therapeutics For Rare Diseases 3/22/2023

   Invitae (NYSE: NVTA), a leading medical genetics company, and Deerfield Management Company, a healthcare investment firm, today announced a partnership to advance genetics-based drug discovery and development in rare disease.

4. Dewpoint Therapeutics Partners With Novo Nordisk To Explore The Field Of Biomolecular Condensates To Treat Insulin Resistance And Diabetes Progression 3/22/2023

   Dewpoint Therapeutics today announced a research and development partnership with Novo Nordisk to identify drug candidates using Dewpoint's discovery platform related to biomolecular condensates to treat insulin resistance and diabetic complications.

5. Gyros Protein Technologies Introduces New PurePep EasyClean Services To Accelerate Development And Manufacturing Of Peptide-Based Drugs 3/21/2023

   Gyros Protein Technologies AB, a leading provider of peptide synthesizers and reagents, and a pioneer in automated nanoliter-scale immunoassays, today announced the launch of three service offerings to support the development and manufacturing of peptide-based drugs.

6. Lumicell Submits New Drug Application For LUMISIGHT Optical Imaging Agent To U.S. FDA For Intraoperative Breast Cancer Detection And Removal 3/21/2023

   Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies for cancer surgery, today announced a New Drug Application (NDA) for its LUMISIGHT Optical Imaging Agent has been submitted to the U.S. Food and Drug Administration (FDA).

7. Altasciences Selects Proscia To Accelerate The Development Of Life-Saving Drugs 3/21/2023

   Proscia®, a leading provider of digital and computational pathology solutions, today announced that Altasciences, a forward-thinking contract research organization (CRO), has chosen Concentriq® for Research to help its sponsors get life-saving therapeutics to patients sooner.

8. NVIDIA Unveils Large Language Models And Generative AI Service To Advance Life Sciences R&D 3/21/2023

   NVIDIA today announced an expanded set of generative AI cloud services for customizing AI foundation models to accelerate the creation of new proteins and therapeutics, as well as research in the fields of genomics, chemistry, biology and molecular dynamics.

9. Sensei Biotherapeutics Announces Submission Of Investigational New Drug (IND) Application For SNS-101, A Conditionally Active VISTA-Blocking Antibody 3/21/2023

   Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 1/2 clinical trial of SNS-101, a conditionally active VISTA-blocking antibody, in patients with solid tumors.

10. Arrowhead Receives FDA Fast Track Designation For ARO-APOC3 3/20/2023

    Arrowhead Pharmaceuticals Inc. today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ARO-APOC3 for reducing triglycerides in adult patients with familial chylomicronemia syndrome (FCS).